ishares

Precious metal ETFs have largely centred on gold stocks, and the outlook for that precious metal remains uncertain. Still for aggressive investors who want to hold precious metal ETFs, here are two that offer top-quality global miners and low fees.
ISHARES MSCI TAIWAN INDEX FUND, $58.75, is a buy for aggressive investors. The ETF (New York symbol EWT; buy or sell through brokers) gives you direct exposure to some of the top public companies of this East Asian powerhouse economy.


The fund’s largest holding is Taiwan Semiconductor at 23.6% of assets....
The major Canadian and U.S. stock markets, while still subject to volatility, continue to offer attractive prospects for investors—especially if you buy the top stocks. All in all, we think that if you can afford to stay in the market for several years or longer, now is a good time for new buying....
iShares S&P/TSX 60 Index ETF Canada Index Fund is your best choice for holding a basket of major Canadian stocks.
Saudi Arabia has ambitious plans to reduce its dependence on oil by generating more sources of income for the government and the citizens of the country. These plans include the opening of various avenues for domestic and international tourism, and a focus on new industries such as electric vehicles, datacentres, and artificial intelligence....
With today’s still-low interest rates, there are few, if any, high return, lower-risk fixed-income investments available to investors right now.


Note that we don’t recommend “going into cash” in times of market uncertainty—or when markets are close to or hitting highs: Going into cash in reaction to uncertainty is rarely a good idea....
ISHARES CORE MSCI ALL COUNTRY WORLD EX CANADA INDEX ETF $45.53 (Toronto symbol XAW; TSINetwork ETF Rating: Aggressive; Market cap: $2.9 billion) invests globally in publicly listed companies, excluding Canada.


The ETF tracks the MSCI ACWI ex-Canada Index....
Biotechnology companies have been at the forefront of some of the most exciting developments in healthcare over the past two decades—and there are more developments in the pipeline. However, the high cost of product development, long lead times for product testing and regulatory approvals, and low success rates add to their risk.


Here are two ETFs that aim to benefit from the opportunities presented by biotech firms despite those challenges....
A Member of Pat McKeough’s Inner Circle asked for his advice on an ETF that focuses on Canadian finance firm common shares, preferred shares and corporate bonds.

Pat likes the high distribution rate but warns that rate may be unsustainable....
iShares MSCI Germany Fund & Australia ETF broaden your horizons with access to top companies from both hemispheres.